FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

MARKSANS

86.4
-0.35 (-0.4%)
Updated 03:29 23/07 IST

MARKSANS Buy or Sell - FrontPage Forums

4 Users have submitted 4 trade ideas of Rs. 257,807.8 for MARKSANS
Disclaimer
100% Bullish
0% Bearish

MARKSANS Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See MARKSANS Share Price Targets >>

MARKSANS Ratings

Long term MARKSANS rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live MARKSANS message board: Is MARKSANS buy or sell? Should I buy MARKSANS shares? Why are MARKSANS shares falling? Should I invest in MARKSANS stock?

  1. Home
  2. MARKSANS Forum

MARKSANS Share Price Discussion

Like
Reply
Like
Reply

MARKSANS PHARMA

CMP : 88.45
Support at 84.8

Good contraction going on, expecting a breakout

#MARKSANS #NSE #BSE #TRADER #BREAKOUTS
MARKSANS - 3938429
Like
Reply

Type
Buy
Instrument
MARKSANS
Entry Price
₹88.1
Price@Trade
₹88.1
Target Price
₹120
Stop Price
₹65
Valid Till
Jul 19, 2022 3:20 AM
Margin
₹105,720 approx for 1200 Qty
Status
Active

Like
Reply
swap_vert
Trade
G
Reputation: 3,659 • Jul 18 2:58 AM

An analyst specialising in long-term picks recommends TVS Electronics, Jubilant Industries (JIVANJOR), Marksans Pharma, Hemisphere Properties and Shemaroo Entertainment for multi-bagger gains.

Like
Reply

Type
Buy
Instrument
MARKSANS
Entry Price
₹87.85
Price@Trade
₹87.85
Target Price
₹100
Stop Price
₹86.5  ₹88.25
Valid Till
Jul 15, 2022 3:20 AM
Margin
₹878,500 approx for 10000 Qty
Status
Stoploss Hit
Exit Price
88.25
Net P&L
+₹4,000 (+0.46%)
Like
Reply (3)
swap_vert
Trade
See all replies

Update
Stoploss Trailed
Price @ Update
₹87.9
Original SL
₹86.5
New SL
87.5

Update
Stoploss Trailed
Price @ Update
₹88.45
Original SL
₹87.5
New SL
88.25
TrackerBot @trackerbot
Jul 16 4:46 AM

Update
Stoploss Hit
Exit Price
88.25
R
Reputation: 72 • Jul 15 5:20 AM
Like
Reply
Like
Reply
4
Reputation: 16 • Jul 5 8:26 AM
Like
Reply
Like
Reply
H
Reputation: 0 • Jun 30 8:25 AM

Type
Buy
Instrument
MARKSANS
Entry Price
₹86.5
Price@Trade
₹86.4
Target Price
₹100
Stop Price
₹75
Valid Till
Jun 30, 2022 3:20 AM
Margin
₹86,500 approx for 1000 Qty
Status
Exited
Exit Price
₹90
Net P&L
+₹3,500 (+4.05%)

Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 30 8:26 AM

Update
Trade Entered
Entry Price
₹86.5
Hiren @Hiren4929
Jul 5 4:39 AM

Update
Exited
Exit Price
₹90
Net P&L
+₹3,500 (+4.05%)
R
Reputation: 72 • Jun 30 4:16 AM
Like
Reply
Like
Reply
Like
Reply
R
Reputation: 72 • Jun 29 5:29 AM
Like
Reply
H
Reputation: 0 • Jun 28 7:36 AM

Type
Buy
Instrument
MARKSANS
Entry Price
₹88
Price@Trade
₹87.85
Target Price
₹150
Stop Price
₹70
Valid Till
Jun 28, 2022 3:20 AM
Margin
₹88,000 approx for 1000 Qty
Status
Exited
Exit Price
₹88.4
Net P&L
+₹400 (+0.45%)

Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 28 7:37 AM

Update
Trade Entered
Entry Price
₹88
Hiren @Hiren4929
Jun 29 7:27 AM

Update
Exited
Exit Price
₹88.4
Net P&L
+₹400 (+0.45%)
S
Reputation: 3,097 • Jun 27 9:43 AM
Shivansh in HDFCBANK
Dividends with Purpose and Ex Dates #HDFCBANK ...
3
Reply

Type
Buy
Instrument
MARKSANS
Entry Price
₹87
Price@Trade
₹87.5
Target Price
₹120
Stop Price
₹78
Valid Till
Jul 23, 2021 3:20 AM
Margin
₹87,000 approx for 1000 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 25 8:35 AM

Update
Trade Entered
Entry Price
₹87
H
Reputation: 0 • Jun 24 7:48 AM

Type
Buy
Instrument
MARKSANS
Entry Price
₹86.85
Price@Trade
₹86.85
Target Price
₹120
Stop Price
₹70
Valid Till
Jun 24, 2022 3:20 AM
Margin
₹86,850 approx for 1000 Qty
Status
Exited
Exit Price
₹87.6
Net P&L
+₹750 (+0.86%)

Like
Reply (1)
swap_vert
Trade
See all replies
Hiren @Hiren4929
Jun 25 5:58 AM

Update
Exited
Exit Price
₹87.6
Net P&L
+₹750 (+0.86%)
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • MARKSANS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization1,295.43
    Enterprise Value1,361.58
    Price to Earnings104.22
    Price to Book Value3.02
    Return on Capital Employed0.05
    Return on Equity0.03
    Face Value1
    Dividend YieldNA
  • MARKSANS - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    11-Jun-18CentrumHold31
    22-Feb-18CentrumBuy55
    30-Sep-16Dynamic LevelsBuy70
    29-Sep-16CentrumBuy60
    MARKSANS Brokerage Price Target
  • MARKSANS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 238787.4586.0586.4
    Jul 2287.788.1586.2586.75
    Jul 2089.390.58686.9
    Jul 1987.9590.987.588.45
    Jul 1686.389.386.1588.1
  • MARKSANS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹87.4
    30 Day Moving Average₹87.62
    50 Day Moving Average₹81.74
    100 Day Moving Average₹70.82
    200 Day Moving Average₹63.6
  • MARKSANS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue294.66215.840.37
    Operating Profit36.4524.190.51
    Profit Before Tax16.6512.580.32
    Net Income12.4312.230.02
  • MARKSANS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds428.97430.03-0
    Total Liabilities127.28128.45-0.01
    Total Assets556.25547.480.02
  • MARKSANS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity23.17-18.67-2.24
    Cash from Investing Activity-7.52-7.8-0.04
    Cash from Financing Activity-17.525.9-1.68
    Net Cash Flow-1.85-0.572.25
  • MARKSANS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.020.02
    Return on Equity0.030.03
    Return on Capital Employed0.050.03
  • MARKSANS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.27
    3 Year CAGR Growth in Operating Profit-0.69
    3 Year CAGR Growth in EBIDTA-0.69
    3 Year CAGR Growth in Net Income-0.81
    3 Yr CAGR Growth - Diluted EPS-0.82
  • MARKSANS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.53
    5 Year CAGR Growth in Operating Profit-0.18
    5 Year CAGR Growth in EBIDTA-0.24
    5 Year CAGR Growth in Net Income-0.69
    3 Yr CAGR Growth - Diluted EPS-0.71
  • MARKSANS - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 11 4:31 AM
    Marksans Pharma hits upper cicuit as company considers preferential allotment
    The Economic Times
    NewsBot
    Oct 14, 2020 10:08 AM
    Ashish Kacholia buys nearly 51 lakh shares of Marksans Pharma in September quarter
    Moneycontrol
    NewsBot
    Jun 8, 2020 9:21 AM
    Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical
    The Economic Times
    NewsBot
    Jun 8, 2020 7:18 AM
    Marksans Pharma recalls 11,279 bottles of diabetes drug due to cancer causing chemical
    Moneycontrol
    NewsBot
    Feb 11, 2020 6:38 AM
    Marksans Pharma gets EIR from USFDA for New York unit
    Moneycontrol
    NewsBot
    Jun 6, 2019 10:08 AM
    NewsBot
    Jun 6, 2019 9:38 AM
    NewsBot
    Mar 7, 2019 7:52 AM
    NewsBot
    Nov 17, 2018 10:47 AM
  • MARKSANS - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020